Phen’X Technologies has sold a majority stake to Ciclad

The shareholders of Phen’X Technologies have completed a primary majority LBO with private equity fund Ciclad.

Founded in 2011, Phen’X Technologies is specialized in medical subcontracting of implants and instruments for dental, maxillofacial and orthopedic applications. With two production sites in France and Portugal, the company manufactures a wide range of components to support surgeons in dental implantology, facial remodeling and orthopedics. The firm also assists its clients in industrialization projects, from the realization of 3D plans and prototypes to the machining of mass-produced parts.

Ciclad is a long-standing, independent private equity investor supporting the growth of small and mid-sized companies in France and abroad. Established in 1988, Ciclad has invested alongside more than 180 executives and management teams. It is involved in buy-outs and capital strengthening, particularly complex transactions such as spin-offs and carveouts, in contexts of strong development – organic growth and build-up – and turnarounds.

Oaklins’ team in France acted as the exclusive financial advisor to the shareholders of Phen’X Technologies in this LBO.